The Supreme Court set a precedent holding that a new crystalline form of a known compound is not worthy of patent protection as the publication of the compound’s name is sufficient to destroy novelty and inventive step from the crystalline forms or hydrates of said compound. The court ordered revocation of the patent’s claim covering the active ingredient in one of the Appellant’s best selling drugs, Fosalan (Fosamax).